J. Miguel Oliveira BSc, PhD, FBSE (Portuguese, M, 48 years old) is a Principal Investigator with Habilitation at the 3B's Research Group, member of the PT Government Associate Laboratory ICVS/3B’s (https://3bs.uminho.pt/people/94) and Institute 3Bs (I3Bs), University of Minho (Portugal). He is the Vice President of I3Bs, President Elect of the Scientific Council of I3Bs. Currently, he is a Lecturer in Doctoral Program in Tissue Engineering, Regenerative Medicine and Stem Cells (TERM&SC) at UMinho, PT (since Dec. 2013). He was also an invited lecturer at the Faculty of Medicine, U. Porto (2013-2019). In addition, he was member of the National Ethics Committee for Clinical Trials from Serviço Nacional de Saúde (SNS) (PORTUGAL) (Jan. 2021- Aug. 2024). Currently, he is an Expert and member of the Steering Committee of the ERA Working Group 4 (WG4: Openness and awareness) of the new policy action “Accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices”, contributing to policies on standardisation, openness and research quality (2026-2029).
Research Area
Medical biotechnology
Background
He is a Biochemist with post graduation in Biomedical Engineering.
J. Miguel Oliveira BSc, PhD, FBSE (Portuguese, M, 48 years old) is a Principal Investigator with Habilitation at the 3B's Research Group, member of the PT Government Associate Laboratory ICVS/3B’s (https://3bs.uminho.pt/people/94) and Institute 3Bs (I3Bs), University of Minho (Portugal). He is the Vice President of I3Bs, President Elect of the Scientific Council of I3Bs. Currently, he is a Lecturer in Doctoral Program in Tissue Engineering, Regenerative Medicine and Stem Cells (TERM&SC) at UMinho, PT (since Dec. 2013). He was also an invited lecturer at the Faculty of Medicine, U. Porto (2013-2019). In addition, he was member of the National Ethics Committee for Clinical Trials from Serviço Nacional de Saúde (SNS) (PORTUGAL) (Jan. 2021- Aug. 2024). Currently, he is an Expert and member of the Steering Committee of the ERA Working Group 4 (WG4: Openness and awareness) of the new policy action “Accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices”, contributing to policies on standardisation, openness and research quality (2026-2029).